Mankind Pharma Faces Rs 341.86 Cr Tax Demand

New Delhi: Mankind Pharma Ltd on Wednesday said it has received additional tax demands, including interest, of Rs 341.86 crore from the Income Tax authority.

The company has received orders from the office of the Deputy Commissioner of Income Tax, Central Circle 29, New Delhi dated May 9, 2025 on May 13 and 14, 2025, through IT portal, raising additional tax demands, including interest, of Rs 341.86 crore, Mankind Pharma said in a regulatory filing.

The demand is on account of adjustments made and disallowance of various expenditures under different sections of the Income Tax Act, 1961, it added.

The company said it believes that “the demands under the orders are not tenable in law”, asserting it has adequate factual and legal grounds to substantiate its position and does not expect any material impact on financials or its operations due to the orders.

Mankind Pharma said it would pursue an appeal against the said orders under applicable laws.

Related Posts

Punjab’s Drugs Challenge Shifts, Other States Blamed For Pharma Smuggling

With heroin availability falling, Punjab Police claims the pattern of drug consumption and supply is changing. Pharmaceutical narcotics have now emerged as the state’s biggest drug enforcement challenge. Chandigarh: The…

Spurious drug probe: SIT raids medical store in Bengaluru, detains proprietor

Bengaluru: In a major breakthrough in the illegal pharmaceutical network operating in Karnataka, investigators from the Special Investigation Team (SIT) raided Krupa Health Care at Minerva Circle, seizing a cache…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Punjab’s Drugs Challenge Shifts, Other States Blamed For Pharma Smuggling

Punjab’s Drugs Challenge Shifts, Other States Blamed For Pharma Smuggling

Spurious drug probe: SIT raids medical store in Bengaluru, detains proprietor

Spurious drug probe: SIT raids medical store in Bengaluru, detains proprietor

US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome

US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome

Fujifilm India installs Echelon Smart MRI at Jansons Health in Erode

Fujifilm India installs Echelon Smart MRI at Jansons Health in Erode

Rajasthan to prepare ‘Narcotics Control Vision 2026-29’ to curb drug abuse and trafficking

Rajasthan to prepare ‘Narcotics Control Vision 2026-29’ to curb drug abuse and trafficking

Bracco Imaging expands BubbleGen cell selection with CD3+ T Cell Isolation Kit

Bracco Imaging expands BubbleGen cell selection with CD3+ T Cell Isolation Kit